What Makes Cognition Therapeutics (CGTX) a New Buy Stock
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript
Cognition Tx (CGTX) Q3 2026 Earnings Call Transcript
Cognition Therapeutics Q3 Earnings Call Highlights
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints
Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.